Jeffrey William Henderson bought stock once, on Feb 10, 2025

Jeffrey William Henderson is a director of Becton, Dickinson and Company (BD), a global medical technology firm, where he has served on the board since 2018 and is also chair of the audit committee.( He is the president of JWH Consulting LLC, a business and investment advisory firm focused primarily on the healthcare industry, and currently serves in multiple public company board roles, including chairman of the board of Halozyme Therapeutics, Inc. and director of Qualcomm Incorporated.( Henderson has recently reported insider transactions in BD stock in his capacity as a director, as disclosed in Form 4 SEC filings under the name Henderson Jeffrey William.(

Previously, Henderson served for nearly a decade as chief financial officer of Cardinal Health, Inc., where he also oversaw the company’s China and Canada operations.( Earlier in his career, he held senior financial and operational positions at Eli Lilly & Co. (including vice president and corporate controller and president and general manager of Eli Lilly Canada) and spent about ten years at General Motors in a variety of international leadership roles.( He holds a Bachelor of Science in electrical engineering from Kettering University and a Master of Business Administration from Harvard Business School, and is recognized for his financial, strategic, and international leadership experience in large multinational healthcare and technology companies.(

Written by Perplexity from public sources.